

## Kerri-Ann Limbeek

### Partner

klimbeek@desmaraisllp.com

**NEW YORK** Phone: 212-808-2962 Fax: 212-351-3401



Kerri-Ann Limbeek is a first-chair trial lawyer who focuses on complex technology disputes, including patent infringement cases. Ms. Limbeek represents both plaintiffs and defendants in a wide variety of industries, including pharmaceuticals, medical and surgical devices, consumer products, semiconductor fabrication, computer hardware, software, telecommunications, and video streaming technology. Ms. Limbeek has extensive experience in all stages of litigation, including before the International Trade Commission, U.S. District Courts, and U.S. Courts of Appeals. She has also represented clients in arbitration proceedings, including before the International Chamber of Commerce.

Ms. Limbeek has been recognized by several leading publications for her trial skills and recent success. For example, in 2023, [Law360 recognized Ms. Limbeek as a Rising Star](#)—one of the country's top trial lawyers under the age of 40. Desmarais LLP was also awarded [Law360 IP Practice Group of the Year](#) in 2023 based, in part, on Ms. Limbeek's \$272.5 million jury verdict on behalf of the biotech firm Ravgen against LabCorp. In January 2024, the American Lawyer honored Ms. Limbeek as "Litigator of the Week" for winning a \$57 million verdict for Ravgen against Natera, as lead trial counsel. [\[Read The American Lawyer story\]](#) [Law360](#) also recognized Desmarais LLP in "[Law360's Legal Lions of the Week](#)" for Ms. Limbeek's victory on behalf of Ravgen against Natera. And Ms. Limbeek won the [New York Law Journal Rising Star](#) award in 2024, and the [2025 Life Sciences Patent Network \(LSPN\) Awards](#) honored Ms. Limbeek as Rising Star of the Year, and awarded her \$57 million jury verdict for Ravgen against Natera as Impact Case of the Year.

Ms. Limbeek has notched trial victories for both plaintiffs and defendants. Ms. Limbeek led a patent litigation campaign on behalf of biotech company, Ravgen, that included trial wins against Natera LabCorp and Natera and the successful defense of Ravgen's patents across ten *inter partes review* proceedings. In January 2024, as lead trial counsel, Ms. Limbeek won a \$57 million damages verdict for Ravgen against Natera. At trial, Ms. Limbeek handled both opening and closing, in addition to cross-examining Natera's

#### EDUCATION

The University of Chicago Law School, J.D., 2013, IP Law Society, The Chicago Journal of International Law, Staff Member

The University of Pennsylvania, School of Engineering and Applied Science, B.S.E., Chemical and Biomolecular Engineering, 2010, *cum laude*

#### ADMISSIONS

2014, New York

engineer who developed the accused product and its main technical expert. In September 2022, Ms. Limbeek secured a \$272.5 million jury verdict and an additional \$100 million in enhanced damages based on the jury's finding of willful infringement for a total of \$372.5 million for Ravgen against testing giant LabCorp. Ms. Limbeek tried the case as co-lead counsel with John Desmarais. At trial, Ms. Limbeek examined Ravgen's technical expert and cross-examined LabCorp's technical expert. Ms. Limbeek also represented Ravgen in six other district court cases, achieving settlements with Myriad, Illumina, Quest Diagnostics, PerkinElmer, Roche and Biora.

Ms. Limbeek and her team also won a clean sweep against ten *inter partes* review (IPR) challenges to Ravgen's patents, which included defeating two IPR petitions filed by Quest at the institution phase as well as obtaining final written decisions in instituted IPR proceedings brought by LabCorp, Illumina, and Streck that upheld the validity of every challenged claim. The team also handled the appeals of three of the IPR decisions, and the Federal Circuit affirmed Ravgen's win in each of those three cases.

On the defense side, in May 2026, Ms. Limbeek co-led the complete defense verdict for Abiomed, a J&J subsidiary, in *Maquet Cardiovascular LLC v. Abiomed Inc.*, a case pending since 2017, passed through three firms including Cravath, and twice before the Federal Circuit. She presented the technical case and led the damages defense, including key expert directs and crosses. The result was especially significant: Abiomed conceded the accused products met the asserted claim limitations yet prevailed under the reverse doctrine of equivalents while also winning invalidity under section 112.

In September 2024, Ms. Limbeek successfully defended a consumer electronics company defendant at trial in a patent infringement suit related to encryption technology. The team achieved a complete defense verdict of non-infringement after a one-week jury trial in Austin, Texas putting an end to the plaintiff's claim of \$361 million in damages. Ms. Limbeek handled the damages portion of the case. She successfully excluded all the plaintiff's original damages theories under *Daubert*. At trial, Ms. Limbeek examined the defendant's damages expert and cross-examined plaintiff's technical and damages experts.

In October 2024, Ms. Limbeek represented a consumer electronics company plaintiff in its successful jury trial in Wilmington, DE. The defendant was found to willfully infringe two design patents relating to smartwatches and their chargers.

Ms. Limbeek has also represented clients in state and federal district courts on a pro bono basis, including recently achieving victories in New York Family Court and Immigration Court for a young Ecuadorian immigrant fleeing religious violence in her country. After an evidentiary hearing conducted by Ms. Limbeek, the Court in that case granted Ms. Limbeek's client's petition for guardianship and issued an order with the requisite special findings for the client to apply for special immigrant juvenile status. Ms. Limbeek then won an order in immigration court that fully stopped removal proceedings against her client and will allow the pro bono client to stay in the U.S. with her father going forward. Outside of her work at Desmarais LLP, Ms. Limbeek also acts as a mentor through a legal outreach program.

Before joining Desmarais LLP, Ms. Limbeek was an associate in the Litigation Group in the New York office of Sullivan & Cromwell LLP. While at Sullivan & Cromwell, Ms. Limbeek focused on patent cases, including representing a medical device company in defending infringement claims at a trial before the International Trade Commission.

## Prior Experience

- Associate, Sullivan & Cromwell LLP, New York, New York, 2013-2015

## Courts

- United States District Court for the Eastern District of New York
- United States District Court for the Southern District of New York
- United States Court Appeals for the Federal Circuit
- United States Court Appeals for the Fourth Circuit

## Representative Matters

- Represented biotech company, Ravgen, in patent litigation campaign, including trial wins against LabCorp and Natera and the successful defense of Ravgen's patents in ten *inter partes review proceedings*.
- Represented consumer electronics company defendant in a patent infringement suit related to encryption technology resulting in complete defense verdict at trial.
- Represented consumer electronics company in a patent infringement suit related to design and utility patents on smartwatches, resulting in willful infringement verdict at trial.
- Represented Dutch biotechnology client in arbitration involving recombinant DNA technology before the International Chamber of Commerce.
- Represented consumer electronics company in a patent infringement suit brought by AGIS Software Development in the Eastern District of Texas, helping achieve a favorable result for our client.
- Represented Enzo Life Sciences against, among others, Abbott Laboratories, Affymetrix, Inc., Agilent Technologies, Inc., Becton, Dickinson & Co., Hologic, Inc., Illumina, Inc., Life Technologies, Corp., Roche Molecular Systems, Inc., and Siemens Healthcare Diagnostics Inc. in patent infringement litigations involving nucleic acid based analytical and diagnostic products in a litigation campaign that resulted in over \$100,000,000 of settlements.
- Represented LifeCell Corporation against LifeNet Health in patent infringement litigation involving soft tissue grafts.
- Represented Intellectual Ventures against Canon in patent infringement litigation involving digital camera technology.
- Represented Ferrosan Medical Devices in defending infringement claims in the International Trade Commission.
- Represented Philips Electronics North America in arbitration concerning patent licensing agreements.

## News & Publications

- **"J&J Unit Cleared In Blood Pump Patent Suit In Mass."** - *Law360*, May 28, 2026

- "Masimo Infringed 2 Apple Watch Patents, Jury Finds" - *Law360*, October 25, 2024
- "Apple Doesn't Infringe Digital Identity Patents, Jury Finds" - *Law360*, October 7, 2024
- "Kerri-Ann Limbeek Trial-focused Lead counsel on how a strong story helped Ravgen defeat Natera" - *Life Sciences Intellectual Property Review* - January 25, 2024
- "Desmarais LLP Wins LMG Life Sciences 2023 Patent Impact Case of the Year Award For Ravgen v. LabCorp Case" - Ms. Limbeek lead this team.
- "Litigator of the Week Runners-Up and Shout Outs" - *ALM/Law.com* highlighted Ms. Limbeek's success on behalf of client Ravgen.
- Desmarais LLP Secures Complete Defense Verdict for Abiomed in Blood Pump Patent Trial
- The Life Sciences Patent Network Recognizes Desmarais LLP
- Desmarais LLP Named Finalist for 7 Life Sciences Patent Network Awards for 2025
- Desmarais LLP Defeats Labcorp's Attempt to Undermine Ravgen's Trial Victory
- Desmarais LLP Earns Appellate Victories for Ravgen's Prenatal Genetic-Testing Patent
- Benchmark Litigation Names John Desmarais to Top 100 Trial Lawyers, Desmarais LLP Ranked as Leading IP Firm
- Kerri-Ann Limbeek Highlighted as a 2024 New York Law Journal Rising Star
- Desmarais LLP Named Finalist for NYLJ's IP Litigation Dept. of the Year Award, Kerri-Ann Limbeek Wins Rising Star Award
- Kerri-Ann Limbeek Named 'Litigator of the Week' for \$57M Patent Trial Victory
- Desmarais LLP Wins \$57M Jury Verdict for Ravgen in Prenatal Genetic Testing Patent Trial
- Desmarais LLP's Trial Training Program Highlighted in Law360
- Kerri-Ann Limbeek Named Law360 Rising Star
- Desmarais LLP Secures \$100M Enhanced Damages Ruling for Ravgen
- Desmarais LLP Wins Pro Bono Ruling to Halt Deportation of Ecuadorian Immigrant
- Desmarais LLP Defeats Final PTAB Challenge to Ravgen's Genetic-Testing Patents
- Desmarais LLP Secures Patent Litigation Settlement for Ravgen
- Law360 IP Practice Group of the Year Award Highlights Desmarais LLP's Trial Wins, Training Program
- Desmarais LLP Secures \$272.5M Jury Verdict in Prenatal Genetic Testing Patent Trial
- Desmarais LLP Announces 2022 Partner Elevations